Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Cancer Type/Condition:  Leukemia, acute myeloid (AML), child
Stage/Subtype:  recurrent childhood acute myeloid leukemia
Country:  U.S.A.
Trial Type:  Treatment
Results 1-25 of 55 for your search:
Start Over
Graft-Versus-Host Disease Prophylaxis in Treating Patients with Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant
Status: Active
Phase: Phase III
Type: Biomarker/Laboratory analysis, Supportive care, Treatment
Age: not specified
Trial IDs: 2448.00, NCI-2010-02035, NCT01231412
Alemtuzumab Before Donor Stem Cell Transplant in Treating Patients With Hematologic Diseases
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 70 and under
Trial IDs: HIMSUM, NCI-2012-00639, NCT00058825
Low-Dose Donor Bone Marrow Transplant in Treating Patients with Hematologic Malignancies
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 6 montha to 70
Trial IDs: J1055, NCI-2011-00377, NA_00039823 / CIR00009182, NCT01203722
Laboratory-Treated T Cells in Treating Patients with High-Risk Relapsed Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia Previously Treated with Donor Stem Cell Transplant
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: Not specified
Trial IDs: 2498.00, NCI-2011-03362, 2498, NCT01640301
Conventional and Regulatory T Cells in Treating Patients With Advanced Hematologic Malignancies Undergoing T Cell-Depleted Donor Stem Cell Transplant
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 13 to 60
Trial IDs: BMT236, NCI-2011-03025, NCT01660607
Donor Natural Killer Cells in Treating Patients with Relapsed or Refractory Acute Myeloid Leukemia
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 2 to 59
Trial IDs: 2012-0079, NCI-2014-00883, NCI-2014-00841, NCT01787474
Donor Natural Killer Cells and Donor Stem Cell Transplant in Treating Patients with High Risk Myeloid Malignancies
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 65 and under
Trial IDs: 2012-0819, NCI-2013-00993, RP110553-P3), NCT01823198
AC220 With 5-Aza or Low Dose Cytarabine
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: Not specified
Trial IDs: 2012-1047, NCI-2013-02274, P50CA100632, NCT01892371
Selinexor, Fludarabine Phosphate, and Cytarabine in Treating Younger Patients with Refractory or Relapsed Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndromes
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 24 and under
Trial IDs: SELHEM, NCI-2014-01704, NCT02212561
Multitargeted Tyrosine Kinase Inhibitor PLX3397 in Treating Younger Patients with Refractory Leukemias or Solid Tumors
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 3 to 30
Trial IDs: 15-C-0093, NCI-2015-00457, 150093, P141640, NCT02390752
Panobinosta, Fludarabine Phosphate, and Cytarabine in Treating Younger Patients with Refractory or Relapsed Acute Myeloid Leukemia or Myelodysplastic Syndrome
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 24 and under
Trial IDs: PANAML, NCI-2016-00098, NCT02676323
Fludarabine, Cyclophosphamide, and Total-Body Irradiation in Treating Patients Who Are Undergoing an Umbilical Cord Blood Transplant for Hematologic Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: 55 and under
Trial IDs: MT2005-10, NCI-2010-01444, 2005LS043, UMN-2005LS043, UMN-BMT-MT2005-10, UMN-MT2005-10, UMN-0507M71475, NCT00309842
Low-Dose Chemotherapy, Low-Dose Total-Body Irradiation, and Anti-Thymocyte Globulin Followed by Donor Bone Marrow Transplant in Treating Patients with Hematologic Malignancy or Kidney Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: Under 70
Trial IDs: MT2001-10, NCI-2010-02155, 0108M06725, 2001LS058, UMN-2001LS058, UMN-MT2001-10, NCT00303719
Fludarabine Phosphate, Cyclophosphamide, Total Body Irradiation and Anti Thymocyte Globulin before Umbilical Cord Blood Transplantation in Treating Patients with Hematological Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: Under 70
Trial IDs: MT2005-02, NCI-2010-01415, 2005LS036, UMN-2005LS036, UMN-MT-2005-02, UMN-0507M70121, NCT00305682
Busulfan, Melphalan, and Fludarabine Phosphate Followed by Donor Umbilical Cord Blood Transplant in Treating Younger Patients with High-Risk Acute Leukemia or Myelodysplastic Syndrome
Status: Active
Phase: Phase II
Type: Treatment
Age: 2 and under at diagnosis
Trial IDs: MT2005-25, NCI-2010-02159, 2005LS075, CPRC #2005LS075, HS# 0511M77206, UMN-2005LS075, UMN-MT2005-25, UMN-0511M77206, NCT00357565
Donor Umbilical Cord Blood Transplant in Treating Patients with Hematologic Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: Any age
Trial IDs: 2239.00, NCI-2009-01551, 2239, FHCRC-2239.00, 6722, FHCRC-IR-6722, NCT00723099
Treosulfan, Fludarabine Phosphate, and Total-Body Irradiation in Treating Patients with Hematological Cancer Who Are Undergoing Umbilical Cord Blood Transplant
Status: Active
Phase: Phase II
Type: Treatment
Age: Under 65
Trial IDs: 2275.00, NCI-2010-00299, 2275, FHCRC-2275.00, IR-6800, NCT00796068
Immune Response after Stem Cell Transplant in HIV-Positive Patients with Hematologic Cancer
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 75 and under
Trial IDs: 2212.00, NCI-2009-01244, 2212, NCT00968630
Sirolimus, Cyclosporine, and Mycophenolate Mofetil in Preventing Graft-versus-Host Disease in Treating Patients with Hematologic Malignancies Undergoing Donor Peripheral Blood Stem Cell Transplant
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Supportive care, Treatment
Age: Not specified
Trial IDs: 2206.00, NCI-2010-02222, NCT01251575
Clofarabine and Low-Dose Total-Body Irradiation in Treating Patients with Acute Myeloid Leukemia Undergoing Donor Peripheral Blood Stem Cell Transplant
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: not specified
Trial IDs: 2430.00, NCI-2010-02247, NCT01252667
Leuprolide Acetate in Improving Immune Recovery and 18F FLT PET/CT in Predicting Immune Recovery after Donor Bone Marrow Transplant in Patients with Hematologic Malignancies
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 9 to 55
Trial IDs: 11-C-0136, NCI-2013-01485, 110136, P10780, NCT01338987
Clofarabine, Busulfan and Fludarabine Phosphate Followed by Donor Stem Cell Transplant in Treating Young Patients With High Risk Hematological Malignancies or Hematological Disorders
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 3 months to 30 years
Trial IDs: CC #110819, NCI-2012-00800, NCT01596699
Azacitidine and Sargramostim as Maintenance Therapy in Treating Patients with Poor-Risk Acute Myeloid Leukemia or Myelodysplastic Syndrome That Have Undergone Stem Cell Transplant or Received Cytarabine-Based Chemotherapy
Status: Active
Phase: Phase II
Type: Treatment
Age: 6 months and older
Trial IDs: J1240, NCI-2014-01349, NA_00072223, NA_00072223_AM00039689, NCT01700673
Start Over